生物工程M13噬菌体-GelMA构建体在脓毒症临床前模型中调节免疫反应
该研究在雄性C57BL/6小鼠(8-10周,22-25 g)中随机分为六组,包括假手术+生理盐水、CLP+生理盐水、CLP+M13、3D-M13、3D+M13和3D+M13+CLP,CLP用于诱导多微生物脓毒症。载细胞的三维生物打印GelMA支架含或不含M13噬菌体,在脓毒症诱导前35天手术植入脾脏。与仅GelMA支架相比,含M13支架表现出更好的可打印性、机械稳定性、细胞性和血管生成。植入3D+M13支架的小鼠促炎细胞因子TNF-α和IL-6水平显著降低,抗炎细胞因子IL-10和TGF-β水平升高,细菌负荷减少,肝、肺、肾损伤减轻,循环肝酶水平降低。作者认为将M13噬菌体整合入GelMA生物墨水可同时增强人工淋巴组织稳定性并刺激抗炎免疫调节。
要点
- 在CLP脓毒症小鼠中,脾脏植入含M13噬菌体的3D打印GelMA支架(3D+M13)较仅GelMA支架显著降低促炎细胞因子TNF-α和IL-6水平。
- 3D+M13组抗炎细胞因子IL-10和TGF-β水平高于仅GelMA支架组。
- 3D+M13组细菌负荷减少,肝、肺、肾损伤减轻,循环肝酶水平降低。
- 含M13支架较仅GelMA支架表现出更好的可打印性、机械稳定性、细胞性和血管生成。
- 该研究为临床前小鼠模型,尚不能直接转化为临床脓毒症治疗推荐。
适用人群与场景
- 雄性C57BL/6小鼠,8-10周龄,体重22-25 g,用于CLP诱导的多微生物脓毒症临床前模型。
处置流程与药物剂量
- 在脓毒症诱导前35天,将载细胞的三维生物打印GelMA支架(含或不含M13噬菌体)手术植入脾脏。
研究设计与关键结果
- 研究类型为临床前动物实验,雄性C57BL/6小鼠随机分为六组:假手术+生理盐水、CLP+生理盐水、CLP+M13、3D-M13、3D+M13和3D+M13+CLP。
- 与仅GelMA支架相比,含M13支架表现出更好的可打印性、机械稳定性、细胞性和血管生成。
- 植入3D+M13支架的小鼠促炎细胞因子TNF-α和IL-6水平显著降低,抗炎细胞因子IL-10和TGF-β水平升高。
- 3D+M13组细菌负荷减少,肝、肺、肾损伤减轻,循环肝酶水平降低。
证据类型、等级与局限
- 证据类型:临床前动物实验(小鼠CLP脓毒症模型)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 该临床前研究结果尚不能改变急诊或ICU脓毒症的临床实践;作者认为将M13噬菌体整合入GelMA生物墨水可同时增强人工淋巴组织稳定性并刺激抗炎免疫调节,为免疫调节和组织工程领域多功能生物材料开发提供了新思路。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
A life-threatening condition, sepsis is defined by dysregulated immune system responses and multi-organ dysfunction. There is still no drug or treatment that can completely guarantee to cure this condition; available treatments mainly focus on controlling the infection with antibiotics, supporting organ function, and managing symptoms. Although artificial lymphoid tissues (aLTs) have potential for localized immunomodulation, their application is often limited by inadequate biological function and poor structural integrity. To address these issues, we developed a novel bioink that combines gelatin methacryloyl (GelMA) with M13 bacteriophage, a filamentous, nonlytic virus recognized for its immunomodulatory activity, self-assembling capacity, and biocompatibility. Male C57BL/6 mice (8-10 weeks, 22-25 g) were randomly assigned to six groups: sham + normal saline (NS), cecal ligation and puncture (CLP) + NS, CLP + M13, 3D - M13, 3D + M13, and 3D + M13 + CLP. The CLP procedure was applied to induce polymicrobial sepsis. Cell-laden, three-dimensional (3D) bio-printed GelMA scaffolds with or without M13 bacteriophage were surgically implanted on the spleen 35 days before sepsis induction. Subsequently, immune, histological, and biochemical parameters were assessed. Compared with GelMA-only scaffolds, M13-containing scaffolds demonstrated improved printability, mechanical stability, cellularity, and angiogenesis. Mice implanted with 3D + M13 scaffolds exhibited significantly reduced levels of proinflammatory cytokines, tumor necrosis factor alpha, and interleukin-6, as well as higher levels of anti-inflammatory cytokines interleukin-10 and transforming growth factor beta. Additionally, the bacterial load was reduced, and organ injury in the liver, lungs, and kidneys was reduced. Circulating liver enzyme levels were also reduced, suggesting precautionary measures against sepsis-induced hepatic dysfunction. The integration of M13 bacteriophage into GelMA bioink is a distinctive approach that simultaneously enhances the stability of artificial lymphoid tissue and stimulates anti-inflammatory immune modulation. This dual structural-immunological effect defines a new paradigm for the development of multifunctional biomaterials in the fields of immune regulation and tissue engineering.
参考来源
- Rahimi A, Soudi S, Vakilian S, et al. Bioengineered M13 Bacteriophage-Gelma Construct Modulates Immune Responses in a Preclinical Model of Sepsis. Shock. 2025. PMID: 41575245. doi:10.1097/SHK.0000000000002787
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。